Handelsavisen
prelaunch
Companies ›Consumer Non Cyclicals ›357A.T
35
357A.T — Tokyo Stock Exchange Drug Retailers

357a.T

¥0,00
Open in Charts → Attach watcher ⌖
— —
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
4,4 %
ROE
34,1 %
Net margin
3,7 %
Debt / equity
1,27
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

357A.T operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals, over-the-counter medications, and related health and wellness products.

Business. 357A.T operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals, over-the-counter medications, and related health and wellness products.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryDrug Retailers
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
34,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 357A.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 357A.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    357A.T operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals, over-the-counter medications, and related health and wellness products.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryDrug Retailers
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    357A.T maintains a strong liquidity position, with cash and equivalents amounting to ¥881.78 million, representing 25.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with free cash flow of ¥244.37 million and total liabilities of ¥2,861.91 million, indicating a liquidity buffer of 8.5%. The current ratio of 1.33 suggests the company can cover its short-term obligations with its current assets.

    Profitability metrics show that 357A.T generates a return on equity (ROE) of 34.09%, significantly above the industry median for drug retailers. The return on assets (ROA) of 5.99% is also strong, indicating efficient use of assets to generate profit. The company's operating margin is 4.41% (¥247.36 million operating income on ¥5,606.20 million revenue), which is in line with the industry's median operating margin.

    The company's revenue is concentrated in its core drug retailing operations, with no disclosed geographic diversification in the latest financials. This suggests a high degree of revenue concentration in its primary market, which could expose the company to regional economic or regulatory risks.

    Looking ahead, 357A.T is projected to maintain a stable growth trajectory, with revenue expected to remain relatively flat in the next fiscal year. The company's capital expenditure of ¥81.17 million is modest, suggesting a conservative approach to reinvestment. The company's operating cash flow of ¥477.36 million supports its capital structure and provides flexibility for future growth initiatives.

    Risk factors for 357A.T include potential regulatory changes in the drug retailing sector and competitive pressures from larger national chains. The company's liquidity risk is low, supported by strong cash reserves and a manageable debt-to-equity ratio of 1.27. There is no immediate dilution risk, as shares outstanding remain unchanged between basic and diluted shares.

    Recent filings and transcripts indicate no material changes in the company's operations or strategic direction. The company continues to focus on maintaining its market position through service quality and product diversification.

    Key takeaways
    • 357A.T maintains a strong liquidity position with cash and equivalents covering 25.4% of total assets.
    • The company's ROE of 34.09% is significantly above the industry median, indicating strong profitability.
    • Revenue is concentrated in the core drug retailing business, with no disclosed geographic diversification.
    • The company is projected to maintain stable growth with minimal capital expenditure and no immediate dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥0,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥610.5M
    Net cashⓘ
    ¥107.8M
    Current ratioⓘ
    1.3
    Debt / equityⓘ
    1.3
    ROAⓘ
    6.0%
    ROEⓘ
    34.1%
    Cash conversionⓘ
    229.0%
    CapEx / revenueⓘ
    -1.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin4,4 %Above P75
    Net Margin3,7 %Above P75
    ROE34,1 %Best in class
    Capex / Rev-1,5 %Above median
    D/E1,27Below median
    Cash Conv2,29Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 357A.T Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    357A.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage